Abstract
Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment option. However, disease progression inevitably occurs, driven by EGFR-dependent or EGFR-independent mechanisms of resistance. Platinum-based chemotherapy is the recommended treatment following progression with osimertinib but responses to platinum-based chemotherapy are transient. Salvage therapies, which are used after progression on platinum-based chemotherapy, have poor clinical outcomes in addition to substantial toxicity. In this podcast, we discuss the current treatment landscape and emerging therapeutic options for patients with metastatic EGFR-mutated NSCLC whose disease has progressed following treatment with osimertinib and platinum-based chemotherapy. Podcast audio available for this article.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5579-5590 |
| Number of pages | 12 |
| Journal | Advances in Therapy |
| Volume | 40 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Dec 2023 |
Funding
This commentary and the publication cost, including the journal’s Rapid Service and Open Access Fees, were funded by Daiichi Sankyo Inc. Medical writing support, under the direction of the authors, was provided by Can Huang, PhD, and Vasupradha Vethantham, PhD, on behalf of CMC Affinity, a division of IPG Health Medical Communications, funded by Daiichi Sankyo Inc., in accordance with Good Publication Practice (GPP 2022) guidelines.
Keywords
- Biomarker testing
- EGFR-activating
- EGFR-mutated
- NSCLC
- Non-small cell lung cancer
- Podcast
ASJC Scopus subject areas
- Pharmacology (medical)
